Chemotherapeutic Toxicity Clinical Trial
Official title:
Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer
Radiation therapy is a crucial part in the comprehensive treatment of breast cancer. In recent years, emerging systemic treatment regimens such as HER 2 inhibitors, CDK 4/6 inhibitors, PARP inhibitors, capecitabine and PD1 inhibitors have greatly improved the prognosis of breast cancer and has become the standard treatment for specific populations. A considerable number of patients require both radiotherapy and maintenance systemic therapy. However, it is not clear whether systemic therapy should be synchronized or suspended in radiotherapy，despite that previous basic research shows that some molecular drug therapy and radiotherapy has a clear synergy mechanism. There is an agent need for a definite evidence to evaluate the safety of synchronous treatment, to support clinical diagnosis and treatment and the next step of comprehensive treatment. The implementation of the new radiotherapy technology represented by IMRT takes into account the prescription dose homogenization and the minimization of normal tissue dosage, which provides a certain basis for the combination therapy. Based on the above conditions, this study intends to enroll patients between 18 and 70 years old with chest wall / breast ± lymphatic drainage area and requiring capecitabine, CDK 4/ 6 inhibitor, HER2 targeted therapy or immunotherapy. Radiation and novel systemic therapies would be delivered concurrently. The study aimed at evaluating the safety of combined treatments.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04277650 -
System for High-Intensity Evaluation During Radiotherapy
|
N/A | |
| Recruiting |
NCT05959720 -
Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil
|
||
| Recruiting |
NCT06041477 -
Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC
|
Phase 3 | |
| Recruiting |
NCT06012253 -
The Effect of Home-Based Walking Program on Peripheral Neuropathy, Fatigue and Quality of Life
|
N/A | |
| Recruiting |
NCT06421610 -
OPC5: Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) in Patients With Malignant Pleural Effusion.
|
Phase 1 | |
| Not yet recruiting |
NCT04965532 -
Residual Neuromuscular Block of Rocuronium in Chemotherapy Patients Under Sevoflurane Anesthesia
|
N/A | |
| Completed |
NCT04843410 -
Effect of Exercise in the Management of Peripheral Neuropathy
|
N/A | |
| Enrolling by invitation |
NCT04027478 -
Can Fasting Decrease the Side Effects of Chemotherapy?
|
N/A | |
| Terminated |
NCT04607668 -
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):
|
Phase 3 | |
| Completed |
NCT05635929 -
Oral Mucositis and Quality of Life With a Mucosa Topical Composition in Head & Neck Cancer Patients.
|
N/A | |
| Recruiting |
NCT06357871 -
Role of Renal Biopsy in the Suspicion of Nephrotoxicity of Immunotherapy (Checkpoint Inhibitors) in Solid Cancer
|
||
| Completed |
NCT02996201 -
Electronic Patient Reporting of Side Effects to Chemotherapy: A Cluster Randomized Controlled Trial
|
N/A | |
| Completed |
NCT00292526 -
Prevention of Chemotherapy-induced Cardiotoxicity in High-risk Patients
|
Phase 4 | |
| Completed |
NCT04663178 -
Foot Bath and Chemotherapy Induced Fatigue
|
N/A | |
| Recruiting |
NCT03191461 -
Myocardial Perfusion and Fibrosis in Cancer Survivors
|
||
| Recruiting |
NCT05251922 -
Tolerance of Anti-Cancer Therapy in the Elderly
|
||
| Not yet recruiting |
NCT06387901 -
Investigating Paclitaxel Toxicity in Breast Cancer: The Roles of Physical Activity and Body Composition.
|
||
| Recruiting |
NCT05892146 -
Strategy Therapy on Cancer Therapy-Related Cardiac Dysfunction
|
N/A | |
| Not yet recruiting |
NCT05921149 -
Fasting Mimicking Diet (FMD) in Conjunction With Chemotherapy in Advanced Ovarian Cancer
|
N/A | |
| Recruiting |
NCT05302336 -
AC vs TC in Patients With HR-positive, HER2-negative Early Breast Cancer
|
Phase 4 |